Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Leukemia, Myeloid, Acute 40Leukemia 30Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Hematologic Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma 11Febrile Neutropenia 10Myelodysplastic Syndromes 9Recurrence 8Neoplasms 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Promyelocytic, Acute 7Neoplasm, Residual 6Neutropenia 5Neoplasms, Plasma Cell 4Graft vs Host Disease 4Philadelphia Chromosome 3Mycoses 3Lymphoma, Mantle-Cell 3Leukemia, B-Cell 3Invasive Fungal Infections 3Bronchiolitis Obliterans Syndrome 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Vomiting 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tumor Lysis Syndrome 2

Interventions

ruxolitinib 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Thalassemia × Other hematologic neoplasm × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡